HGCapital Hg Capital Hg Capital 6200000 2021 20210729 competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
The Competition and Markets Authority (CMA) found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency. The agency also fined two private equity firms, HGCapital and Cinven, that previously owned parts of the business. UK-CMA Competition and Markets Authority Germany privately held private equity (including portfolio companies) private equity (including portfolio companies) https://www.gov.uk/government/news/cma-fines-pharma-firm-over-pricing-of-crucial-thyroid-drug HGCapital’s fine was reduced to £6.2 million on appeal in 2023 UK21-96060
1